or Try an Advanced Search...

    Treatment Of Parkinson's Disease Stocks List

    Symbol Grade Name % Change
    ITCI A Intra-Cellular Therapies Inc. -6.12
    TEVA B Teva Pharmaceutical Industries -3.03
    ATHE C Alterity Therapeutics Limited 6.47
    CCM C Concord Medical Services Holdings Limited ADS -7.90
    NRSNW C NeuroSense Therapeutics Ltd. - warrant 0.00
    AMRX D Amneal Pharmaceuticals, Inc. -1.56
    IKT D Inhibikase Therapeutics, Inc. -1.41
    VYGR F Voyager Therapeutics, Inc. -2.45
    NERV F Minerva Neurosciences, Inc 1.21
    ACAD F ACADIA Pharmaceuticals Inc. -0.70
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Care
    Related Stock Lists: Parkinson's Disease Alzheimer's Disease Medicine Drugs Neuroscience Schizophrenia Aging Associated Diseases Amyotrophic Lateral Sclerosis Biopharmaceutical Biotechnology Cancer Dementia Depressive Disorder Huntington's Disease Insomnia Major Depressive Disorder Medication Neurological Disorders Pain Pharmaceutical

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Parkinson's Disease stocks.

    Symbol Grade Name Weight
    IBRN D iShares Neuroscience and Healthcare ETF 9.26
    ISRA C Market Vectors Israel ETF 8.86
    EIS C iShares MSCI Israel Capped Investable Market Index Fund 7.82
    FBT D First Trust Amex Biotech Index Fund 6.3
    XPH D SPDR S&P Pharmaceuticals ETF 5.54
    View all Treatment Of Parkinson's Disease ETFs...
    Compare ETFs
    Compare EIS to FBT Compare IBRN to FBT Compare ISRA to XPH

        Treatment Of Parkinson's Disease Stocks Recent News

        Date Stock Title
        Apr 18 TEVA 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
        Apr 18 ITCI Intra-Cellular Therapies drops 2%, prices $500M equity financing
        Apr 18 ITCI Intra-Cellular Therapies Prices Public Offering of Common Stock
        Apr 17 ACAD Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
        Apr 17 ITCI Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point
        Apr 17 ITCI Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
        Apr 17 ITCI Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
        Apr 17 ITCI Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
        Apr 16 TEVA FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
        Apr 16 TEVA Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
        Apr 16 ITCI Intra-Cellular Therapies announces proposed public offering of common stock
        Apr 16 ITCI Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
        Apr 16 ITCI Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
        Apr 16 ITCI UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
        Apr 16 ITCI Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
        Apr 16 ITCI Intra-Cellular Therapies gains on meeting main goal in trial for its depression treatment
        Apr 16 TEVA Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
        Apr 16 ITCI Intra-Cellular builds case for depression drug with late-stage trial win
        Apr 16 ITCI Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
        Apr 16 VYGR Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Care
        Related Stock Lists: Parkinson's Disease Alzheimer's Disease Medicine Drugs Neuroscience Schizophrenia Aging Associated Diseases Amyotrophic Lateral Sclerosis Biopharmaceutical Biotechnology Cancer Dementia Depressive Disorder Huntington's Disease Insomnia Major Depressive Disorder Medication Neurological Disorders Pain Pharmaceutical
        Treatment Of Parkinson's Disease

        Treatment of Parkinson's disease typically involves a combination of medications, lifestyle changes, and therapies. Medications used to treat Parkinson's disease include levodopa, dopamine agonists, MAO-B inhibitors, anticholinergics, and amantadine. Lifestyle changes may include exercise, diet, and stress management. Therapies such as physical therapy, occupational therapy, speech therapy, and cognitive behavioral therapy may also be used to help manage symptoms.

        Browse All Tags